Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)

Trial Profile

Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)

Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs LY 2795050 (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Pharmacokinetics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 30 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 30 Mar 2016 Status changed from active, no longer recruiting to discontinued as the principal investigator Dr. Alex Neumeister left NYU in March 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top